Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

Masaya Hattori; Hiroshi Ishiguro; Norikazu Masuda; Akiyo Yoshimura; Shoichiro Ohtani; Hiroyuki Yasojima; Satoshi Morita; Shinji Ohno; Hiroji Iwata

doi:10.1007/s12282-017-0815-7

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

Breast Cancer. 2018 Jan;25(1):126. doi: 10.1007/s12282-017-0815-7.

Authors

Masaya Hattori¹, Hiroshi Ishiguro², Norikazu Masuda³, Akiyo Yoshimura¹, Shoichiro Ohtani⁴, Hiroyuki Yasojima³, Satoshi Morita⁵, Shinji Ohno⁶, Hiroji Iwata⁷

Affiliations

¹ Department of Breast Oncology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.
² Department of Target Therapy Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan.
³ Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, 540-0006, Japan.
⁴ Division of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, 730-8518, Japan.
⁵ Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan.
⁶ Breast Oncology Center, Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan.
⁷ Department of Breast Oncology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. hiwata@aichi-cc.jp.

Abstract

The article "Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study", written by Masaya Hattori, Hiroshi Ishiguro, Norikazu Masuda, Akiyo Yoshimura, Shoichiro Ohtani, Hiroyuki Yasojima, Satoshi Morita, Shinji Ohno, and Hiroji Iwata, was originally published electronically on the publisher's Internet portal (currently SpringerLink) on 31 August 2017 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on [9 November 2017] to

©.

Publication types

Published Erratum